Relapse Rates, Time-to-Flare, and Biomarker Predictors Following Omalizumab Gradual De-escalation versus Abrupt Discontinuation in Controlled Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Cohorts. (PubMed, Int Arch Allergy Immunol) - Oct 17, 2026 - "Gradual de-escalation of omalizumab is associated with an almost two-fold reduction in the risk of post-discontinuation relapse relative to abrupt stopping. Baseline total IgE and blood eosinophils emerge as pivotal, endotype-specific biomarkers for judging which patients are ready to stop."
Biomarker • Journal • Observational data • Retrospective data • Review • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|
|
Muhammed Sah Dogan; Ruhat Tunc; Sezgin Yildiz
|